- Home
- PCLA vs PLRX Comparison
PCLA vs PLRX Comparison
Compare PCLA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCLA
- PLRX
- Stock Information
- Founded
- PCLA 2008
- PLRX 2015
- Country
- PCLA Japan
- PLRX United States
- Employees
- PCLA N/A
- PLRX N/A
- Industry
- PCLA Building Products
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PCLA Consumer Discretionary
- PLRX Health Care
- Exchange
- PCLA Nasdaq
- PLRX Nasdaq
- Market Cap
- PCLA 71.3M
- PLRX 77.3M
- IPO Year
- PCLA 2025
- PLRX 2020
- Fundamental
- Price
- PCLA $3.25
- PLRX $1.40
- Analyst Decision
- PCLA
- PLRX Hold
- Analyst Count
- PCLA 0
- PLRX 10
- Target Price
- PCLA N/A
- PLRX $9.79
- AVG Volume (30 Days)
- PCLA 2.4M
- PLRX 1.6M
- Earning Date
- PCLA 01-01-0001
- PLRX 08-06-2025
- Dividend Yield
- PCLA N/A
- PLRX N/A
- EPS Growth
- PCLA N/A
- PLRX N/A
- EPS
- PCLA N/A
- PLRX N/A
- Revenue
- PCLA $5,475,228.00
- PLRX N/A
- Revenue This Year
- PCLA N/A
- PLRX N/A
- Revenue Next Year
- PCLA N/A
- PLRX N/A
- P/E Ratio
- PCLA N/A
- PLRX N/A
- Revenue Growth
- PCLA 40.19
- PLRX N/A
- 52 Week Low
- PCLA $0.37
- PLRX $1.10
- 52 Week High
- PCLA $9.80
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- PCLA N/A
- PLRX 54.68
- Support Level
- PCLA N/A
- PLRX $1.13
- Resistance Level
- PCLA N/A
- PLRX $1.27
- Average True Range (ATR)
- PCLA 0.00
- PLRX 0.11
- MACD
- PCLA 0.00
- PLRX 0.02
- Stochastic Oscillator
- PCLA 0.00
- PLRX 90.00
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.